oral tirzepatide eli lilly orforglipron GLP-1 phase 3 weight loss trial FDA approves Eli Lilly's tirzepatide

Munn, D

There is no need to aspirate (pull back on the plunger) for subcutaneous injections

It delivers a clinically effective L Carnitine dosage that supports fat metabolism, energy production, and post-exercise recovery

Published studies in rodent models have documented effects on tendon-to-bone healing, ligament recovery, muscle crush injury recovery, and gastrointestinal mucosal integrity

Yes not because of the medication itself, but because undernutrition is a real and often overlooked risk factor

BLA for Rockets LAD-I Gene Therapy Under Review by FDA Again October 14, 2025 The FDA has accepted Rocket Pharmaceuticals resubmission of a BLA for marnetegragene autotemcel (RP-L201, to be marketed as Kresladi), a genetically modified autologous hematopoietic stem cell therapy intended to treat LAD-I